JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROLâ"¢, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026. About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and pr ...

Core Viewpoint - Jupiter Neurosciences, Inc. is hosting a webinar to discuss its scientific platform, clinical development plans, and commercial strategy for 2026, focusing on its lead asset JOTROL™ and its dual-path approach in both pharmaceutical and consumer markets [2][4]. Group 1: Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company targeting neuroinflammation and healthy aging through a dual-path strategy [4]. - The company is advancing a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line [4]. - JOTROL™, a proprietary enhanced resveratrol formulation, has shown significantly improved bioavailability compared to earlier resveratrol products [4][5]. Group 2: JOTROL™ and Clinical Development - JOTROL™ achieves over nine times higher bioavailability compared to previous resveratrol formulations, which is critical for its effectiveness [6]. - The company is advancing JOTROL™ toward a Phase IIa clinical trial in Parkinson's Disease, with a broader focus on CNS disorders including Alzheimer's Disease and Friedreich's Ataxia [4][6]. - The Phase I study results of JOTROL™ were published in reputable journals, indicating a strong foundation for upcoming trials [6]. Group 3: Nugevia Product Line - Nugevia™ is a premium longevity and performance supplement line that utilizes the same patented JOTROL™ technology, targeting cognitive health, skin vitality, and cellular energy [8][9]. - Nugevia products are developed under pharmaceutical standards and are based on peer-reviewed clinical data, differentiating them from conventional supplements [9]. - The product line aims to support healthy aging through formulations that enhance cognitive resilience, mitochondrial energy, and skin vitality [8].

Dr. Eric Topol’s longevity work identified daily habits to follow in a study of “super agers” who are healthy at ages 85 and above."I am taking my own advice," says Dr. Topol, a 70-year-old cardiologist.He shares the tips that he follows: 🔗 https://t.co/xslrzbOjpx https://t.co/jv3ND9zLHD ...

Dr. Eric Topol’s longevity work identified daily habits to follow in a study of “super agers” who are healthy at ages 85 and above."I am taking my own advice," says Dr. Topol, a 70-year-old cardiologist.He shares the tips that he follows: 🔗 https://t.co/rj4RsMVZAM https://t.co/SwnI4lZBHj ...

Financial Data and Key Metrics Changes - The company reported a record revenue of $34 million for Q3 2025, representing a 33% increase year over year, and a net income of $4.6 million compared to $1.9 million in the same period last year [5][14][17] - The cash position at the end of the quarter was $64.3 million with no debt [5][17] - Gross margin improved to 64.5%, up 100 basis points from 63.5% a year ago [16] Business Line Data and Key Metrics Changes - E-commerce business generated net sales of $19 million, a 29% increase year over year [5][14] - The distribution business saw a significant growth of 109% year over year, achieving $7 million in revenue [5][14] - Niagen ingredient business remained steady with revenue of $6.9 million, a 4% increase year over year [14] Market Data and Key Metrics Changes - The NAD market is expanding rapidly, with significant opportunities in skincare, cosmetics, food, beverage, and drug applications [8][10] - The company has onboarded over 1,000 wellness and healthcare clinics across the U.S. to offer the Niagen Plus product line [7][8] Company Strategy and Development Direction - The company aims to educate healthcare practitioners and consumers about Niagen as the most effective NAD booster available [6][8] - Plans to expand distribution of at-home injection kits via a telehealth platform are underway [7][34] - The company is considering establishing a standalone entity to pursue pharmaceutical applications of nicotinamide riboside, particularly for Parkinson's disease [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the updated full-year revenue growth guidance, revised from 22%-27% to 25%-30% year-over-year [18] - The company anticipates that gross margins will normalize on a quarterly basis moving forward, despite improvements year-over-year [16][19] - Management noted that the FDA's recent decision regarding NMN has not significantly impacted consumer purchasing behavior [36][37] Other Important Information - The company has over 40 peer-reviewed clinical studies supporting the efficacy of Niagen [9][12] - The National Advertising Division recently supported the company's position against false claims made by competitors regarding NAD products [10] Q&A Session Summary Question: What is the uptake looking like with the new partnership for IV? - Management indicated it is too early to provide feedback as the partnership just began reselling the material [24] Question: How does the "About NAD" site fit into the marketing funnel? - The site serves as an objective resource for information on NAD and is not part of the purchasing funnel [26] Question: Are at-home injection kits available in all clinics? - Currently, the kits are available in clinics, and the rollout for online purchasing is expected to take several months [33] Question: Has the FDA's announcement on NMN changed consumer purchasing behavior? - Management noted no significant changes in purchasing behavior since the announcement [36] Question: Will the company establish a standalone entity for pharmaceutical applications? - Management confirmed that establishing a standalone entity for pharmaceutical pursuits is likely, depending on study results and discussions with pharma companies [42]

Health & Longevity - The study focuses on "super agers," individuals who maintain good health at 85 years and older [1] - Dr Eric Topol, a 70-year-old cardiologist, shares daily habits for longevity [1]

Dr. Eric Topol’s longevity work identified daily habits to follow in a study of “super agers” who are healthy at ages 85 and above."I am taking my own advice," says Dr. Topol, a 70-year-old cardiologist.He shares the tips that he follows: 🔗 https://t.co/Va7FeRF3yp https://t.co/He6CRtZlxH ...

Health & Longevity - The study focuses on "super agers," individuals who maintain good health at 85 years and above [1] - Dr Eric Topol, a 70-year-old cardiologist, shares daily habits for longevity [1] Daily Habits - Dr Topol follows his own advice regarding daily habits for healthy aging [1]

Dr. Eric Topol’s longevity work identified daily habits to follow in a study of “super agers” who are healthy at ages 85 and above."I am taking my own advice," says Dr. Topol, a 70-year-old cardiologist.He shares the tips that he follows: 🔗 https://t.co/c1nMuvmxpl https://t.co/aAL5Ppy602 ...

Dr. Eric Topol’s longevity work identified daily habits to follow in a study of “super agers” who are healthy at ages 85 and above."I am taking my own advice," says Dr. Topol, a 70-year-old cardiologist.He shares the tips that he follows: 🔗 https://t.co/SbEGOm6NNF https://t.co/Hjgdbl0Pdl ...